To examine if PPARδ agonist 5a could alleviate AD-like pathology based on its anti-inflammatory properties, we investigated the therapeutic efficacy of 5a using mice with scopolamine-induced cognitive impairment and 12-month-old APPswe/PSEN1dE9 (APP/PS1) double transgenic mice. The gene discussed is APP; the disease is Alzheimer disease.